Cardiff Oncology (CRDF) vs Champions Oncology (CSBR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Champions Oncology (CSBR) has outperformed Cardiff Oncology (CRDF) over the past year, losing 26.2% versus a loss of 54.6%. Over five years, CSBR leads with a -52.0% price change compared with -83.1% for CRDF. Cardiff Oncology is the larger company by market cap ($84.0 million vs $67.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | CSBR |
|---|---|---|
| Share price | $1.08 | $4.84 |
| Market cap | $84.02M | $67.37M |
| 1-day change | +1.89% | -2.81% |
| YTD return | -61.57% | -29.96% |
| 1-year return | -54.62% | -26.22% |
| 5-year return | -83.13% | -51.98% |
| Forward P/E | — | 48.40 |
| EPS (TTM) | $-0.60 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $8.31 |
| 52-week low | $0.76 | $4.59 |
| Distance from 52-week high | -67.37% | -41.76% |
| Analyst consensus | none | — |
| Avg. price target upside | +437.96% | — |
| Average volume | 1.04M | 11.32K |
| Shares outstanding | 77.80M | 13.92M |
| Employees | 30 | 214 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed CRDF by 28.4 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
CRDF vs CSBR FAQ
Which is bigger, Cardiff Oncology or Champions Oncology?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $84.02M compared with $67.37M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CRDF or CSBR?
CSBR returned -26.22% over the past 12 months, compared with -54.62% for CRDF (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and Champions Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.